By analyzing existing basic indicators between Geovax Labs and Brickell, you can compare the effects of market volatilities on both companies' prices and check if they can diversify away market risk if combined in one of your portfolios. You can also utilize pair trading strategies for matching a long position in Brickell with a short position in Geovax Labs. Check out our
pair correlation module for more information.
Let's begin by analyzing the assets.
The asset utilization indicator refers to the revenue earned for every dollar of assets a company currently reports. Geovax Labs has an asset utilization ratio of 91.62 percent. This suggests that the company is making $0.92 for each dollar of assets. An increasing asset utilization means that Geovax Labs is more efficient with each dollar of assets it utilizes for everyday operations.
Out of tens of thousands of stocks, funds, and ETFs that trade on global exchanges each represent an individual company which you can analyze using comparative analysis. To determine which one of the two entities, such as GeoVax or Home is a better fit for your portfolio, analyzing a few basic fundamental indicators is a good first step.
How important is GeoVax Labs's Liquidity
GeoVax Labs
financial leverage refers to using borrowed capital as a funding source to finance GeoVax Labs ongoing operations. It is usually used to expand the firm's asset base and generate returns on borrowed capital. GeoVax Labs financial leverage is typically calculated by taking the company's all interest-bearing debt and dividing it by total capital. So the higher the debt-to-capital ratio (i.e., financial leverage), the riskier the company. Financial leverage can amplify the potential profits to GeoVax Labs' owners, but it also increases the potential losses and risk of financial distress, including bankruptcy, if the firm cannot cover its debt costs. The degree of GeoVax Labs' financial leverage can be measured in several ways, including by ratios such as the debt-to-equity ratio (total debt / total equity), equity multiplier (total assets / total equity), or the debt ratio (total debt / total assets). Please check the
breakdown between GeoVax Labs's total debt and its cash.
Correlation Between GeoVax and Home Federal Bancorp
In general, Stock analysis is a method for investors and traders to make individual buying and selling decisions. Stock correlation analysis is also essential because it can help investors realize that they may not be as diversified as they think. Risk management strategies are usually required to make sure all portfolios are properly aligned against their risk tolerance level. You can consider holding GeoVax Labs together with similar or unrelated positions with a negative correlation. For example, you can also add Home Federal to your portfolio. If Home Federal is not perfectly correlated to GeoVax Labs it will diversify some of the market risks out of the positively correlated stocks in your portfolio. However, the disadvantage of this sort of hedging is that it can potentially affect your investment returns throughout market cycles. When GeoVax Labs, for example, performs excellent and delivers stable returns, the negatively correlated position you locked in as a hedge may drag your returns down.
Are you currently holding both GeoVax Labs and Home Federal in your portfolio? Please note if you are using this as a pair-trade strategy between GeoVax Labs and Home Federal, watch out for correlation discrepancy over time. Relying on the historical price correlations and assuming that it will not change may lead to short-term losses. Please check
pair correlation details between GOVX and HFBL for more information.
Another angle On GeoVax Labs
Revenue is income that a firm generates from business activities such us rendering services or selling goods to customers. It is a crucial part of a business and an essential item when evaluating a company's financial statements. Revenues from a firm's primary business operations can be reported on the income statement as sales revenue, net sales, or simply sales, depending on the industry in which a given company operates.
Revenue is typically recorded when cash or cash equivalents are exchanged for services or goods and can include product or services discounts, promotions, as well as early payments on invoices or services rendered in advance.
Revenue Breakdown
Let me now analyze Geovax Labs revenue. Based on the latest financial disclosure, Geovax Labs reported 1.22
M of revenue. This is 99.98% lower than that of the Healthcare sector and 99.84% lower than that of the
Biotechnology industry. The revenue for all United States stocks is 99.99% higher than that of the company. As for Brickell Biotech we see revenue of 337
K, which is 99.95% lower than that of the Biotechnology
| GOVX | 1.22 Million | 0.16 |
| Sector | 742.91 Million | 99.79 |
| BBI | 337,000 | 0.0453 |
Our take on today Geovax Labs rise
The variance is down to 26.88 as of today. Geovax Labs exhibits very low volatility with skewness of 1.31 and kurtosis of 6.53. However, we advise investors to further study Geovax Labs technical indicators to make sure all market info is available and is reliable. Understanding different market volatility trends often help investors to time the market. Properly using volatility indicators enable traders to measure Geovax Labs' stock risk against market volatility during both bullying and bearish trends. The higher level of volatility that comes with bear markets can directly impact Geovax Labs' stock price while adding stress to investors as they watch their shares' value plummet. This usually forces investors to rebalance their portfolios by buying different stocks as prices fall.
Geovax Labs Implied Volatility
Geovax Labs' implied volatility exposes the market's sentiment of Geovax Labs stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Geovax Labs' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Geovax Labs stock will not fluctuate a lot when Geovax Labs' options are near their expiration.
Our Takeaway on Geovax Labs Investment
While many other companies under the biotechnology industry are still a bit expensive, Geovax Labs may offer a potential longer-term growth to investors. While some investors may not share our view we believe that the current risk-reward utility is not appealing enough to do any trading. Please use our equity advice module to run different scenarios to ensure your current risk level and investment horizon are fully reflective of your current investing preferences in regards to Geovax Labs.
Building efficient market-beating portfolios requires time, education, and a lot of computing power!
The Portfolio Architect is an AI-driven system that provides multiple benefits to our users by leveraging cutting-edge machine learning algorithms, statistical analysis, and predictive modeling to automate the process of asset selection and portfolio construction, saving time and reducing human error for individual and institutional investors.
Try AI Portfolio ArchitectEditorial Staff
Vlad Skutelnik is a Macroaxis Contributor. Vlad covers stocks, funds, cryptocurrencies, and ETFs that are traded in North America, focusing primarily on fundamentals, valuation and market volatility. He has many years of experience in fintech, predictive investment analytics, and risk management.
View Profile This story should be regarded as informational only and should not be considered a solicitation to sell or buy any financial products. Macroaxis does not express any opinion as to the present or future value of any investments referred to in this post. This post may not be reproduced without the consent of Macroaxis LLC. Macroaxis LLC and Vlad Skutelnik do not own shares of GeoVax Labs. Please refer to our
Terms of Use for any information regarding our disclosure principles.
Would you like to provide feedback on the content of this article?
You can get in touch with us directly or send us a quick note via email to
editors@macroaxis.com
